Day One Biopharmaceuticals (DAWN) Projected to Post Quarterly Earnings on Tuesday

Day One Biopharmaceuticals (NASDAQ:DAWN) is anticipated to post its Q1 2025 quarterly earnings results after the market closes on Tuesday, May 6th. Analysts expect the company to announce earnings of ($0.45) per share and revenue of $30.28 million for the quarter.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.34). The firm had revenue of $29.21 million for the quarter, compared to analyst estimates of $27.11 million. On average, analysts expect Day One Biopharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Day One Biopharmaceuticals Price Performance

NASDAQ:DAWN opened at $7.93 on Friday. Day One Biopharmaceuticals has a 12 month low of $6.41 and a 12 month high of $17.79. The firm has a market capitalization of $803.74 million, a PE ratio of -7.70 and a beta of -1.24. The business’s fifty day moving average price is $7.92 and its 200 day moving average price is $11.35.

Analysts Set New Price Targets

Several brokerages have commented on DAWN. JPMorgan Chase & Co. dropped their price target on shares of Day One Biopharmaceuticals from $39.00 to $34.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 5th. Wedbush reissued an “outperform” rating and issued a $32.00 target price on shares of Day One Biopharmaceuticals in a report on Wednesday, February 26th. Bank of America cut their price target on Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. Needham & Company LLC reaffirmed a “buy” rating and issued a $32.00 target price on shares of Day One Biopharmaceuticals in a report on Wednesday, February 26th. Finally, The Goldman Sachs Group lowered their price objective on shares of Day One Biopharmaceuticals from $39.00 to $27.00 and set a “buy” rating on the stock in a research report on Tuesday, March 25th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $32.29.

Insider Transactions at Day One Biopharmaceuticals

In related news, CFO Charles N. York II sold 4,370 shares of the business’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total transaction of $52,265.20. Following the sale, the chief financial officer now owns 252,638 shares of the company’s stock, valued at approximately $3,021,550.48. The trade was a 1.70 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Jeremy Bender sold 12,048 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total transaction of $144,094.08. Following the completion of the transaction, the chief executive officer now directly owns 128,015 shares of the company’s stock, valued at approximately $1,531,059.40. This trade represents a 8.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 21,064 shares of company stock worth $251,925. Company insiders own 6.20% of the company’s stock.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.